Significance of ER-Src axis in hormonal therapy resistance - Wikidata - wikimedia - TriplyDB

Significance of ER-Src axis in hormonal therapy resistance

Significance of ER-Src axis in hormonal therapy resistance

http://www.wikidata.org/entity/Q28301805

about

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death Minireview: Deciphering the Cellular Functions of PELP1 Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer PELP1 oncogenic functions involve CARM1 regulation PELP1: a review of PELP1 interactions, signaling, and biology PELP1 oncogenic functions involve alternative splicing via PRMT6 Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.Melatonin: an inhibitor of breast cancer.Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.PELP1: Structure, biological function and clinical significance.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved Drug resistance and the role of combination chemotherapy in improving patient outcomes.Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.Membrane-initiated estradiol signaling of epithelial-mesenchymal transition-associated mechanisms through regulation of tight junctions in human breast cancer cells.Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth.Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.Combination of SIRT1 and Src overexpression suggests poor prognosis in luminal breast cancer.

P2860

Q28084585-C6C996E7-C86C-4C27-B3D6-5B842997FE3A Q28237217-B56FA1B7-490B-47FF-BC7C-0FEB5E907E8E Q28251097-8C5AA9EA-7A1F-48C8-BD4D-BD0833C14B09 Q28259195-C7177D2C-639E-4C33-ADEC-5F0B8E4C712F Q28264812-EBEB9E42-0ADC-48C8-BD49-2DD6AF1D35D1 Q28271388-5E371F6B-3042-4EE6-B4C5-1A87EB6CF5A8 Q28287092-7D3584E1-597F-474F-936E-163120B3383B Q28296277-63CAA6C3-2C0B-4C80-A2F9-68939421AD41 Q28306263-367F5425-3EEA-4293-9DEE-D534ED2791D5 Q28306753-CE420D65-926C-4625-81C8-54D4168D0727 Q33992390-3FFDE46B-BAF1-442B-91F7-36A20440A308 Q34099289-FFC3BA4A-C2FC-4674-AB25-6C0F3358B6F7 Q35232564-837AE3BB-616E-4FB6-A7A2-185EBFFD95F0 Q35689110-EC338D67-FC23-4DD9-813C-714D14F8AC7D Q35738599-54F04017-B36E-4EB0-A897-B0EAC293759A Q36053869-33E403F5-537A-4B6A-9F34-2CA25F133C5E Q36818434-25B839F6-F852-4C2B-8723-89A4BDFAEC0D Q36946008-E1BB99B3-98FA-4841-964E-5DFFA8AA31C2 Q36999509-D71B3F8E-B9C9-4DC6-B7D8-846B83468CE0 Q37911312-C8B463F8-CCEB-40BE-BA52-7110C11BD733 Q37992693-AC56C0A2-1CC5-47F7-8420-6BC8202B9B16 Q38192017-67FBE434-8675-441C-A035-D92A03CDC870 Q39000905-6E68464C-B251-4DFC-8C5A-8D51260CCF80 Q39160945-60522C17-5838-453B-8379-3ABF08AF36D8 Q39528363-823E58D3-A016-468A-8364-8A4941281E05 Q41305086-D1274844-84CA-4637-98BF-E047397C0ABA Q47163309-57395A70-DD7D-48CD-8AE4-EF65214E87EE Q47394260-C0861489-126D-4B1C-B59D-E4A2A2100A99 Q55438825-FAF54264-2A48-498D-88EB-D2137824CA04

P2860

Significance of ER-Src axis in hormonal therapy resistance

http://www.wikidata.org/entity/Q28301805

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Significance of ER-Src axis in hormonal therapy resistance

@ast

Significance of ER-Src axis in hormonal therapy resistance

@en

Significance of ER-Src axis in hormonal therapy resistance

@nl

type

label

Significance of ER-Src axis in hormonal therapy resistance

@ast

Significance of ER-Src axis in hormonal therapy resistance

@en

Significance of ER-Src axis in hormonal therapy resistance

@nl

prefLabel

Significance of ER-Src axis in hormonal therapy resistance

@ast

Significance of ER-Src axis in hormonal therapy resistance

@en

Significance of ER-Src axis in hormonal therapy resistance

@nl

P1433

Q28301805-EA0DFEAC-C0E6-4151-9957-7A068541380A

P1476

Q28301805-628C5D8A-43A9-4DFE-BC1C-4F7BBA677623

P2093

Q28301805-32E017CD-F106-434D-B61F-099384A866E8

Q28301805-5E4E1B38-DBC6-4F92-8B0D-19F2B4350DA5

Q28301805-673CD488-2E92-4263-AD5D-82E016B27681

Q28301805-AE322A90-C866-461C-B48B-B034D18481D3

Q28301805-AECCD26E-A3F8-4B15-AEF6-7F08A1B7E3A5

Q28301805-C4AC1C37-FB91-410C-95B0-80060D2628EE

Q28301805-D6D45BD9-C7DA-4138-82BB-E062D5D14B54

P2860

Q28301805-06E46829-475C-4CEC-BD0B-664DAB325577

Q28301805-0DCB0509-5796-4D95-9E8F-BBA6B543F926

Q28301805-1B5493F3-B183-43BE-8EE5-16A47DEC4723

Q28301805-1D97174B-1F06-4FC0-9F5F-4A03A3765903

Q28301805-1E59DC2D-8191-4BC8-A7B6-488B168BE469

Q28301805-2BAFD768-E430-4BA6-B524-271DBAB742BA

Q28301805-39BFA54D-0A81-4D4B-8262-EA73EB0EED18

Q28301805-3A2FB5C3-BB5A-4CF8-B50E-7532C4721B14

Q28301805-3C93CC89-BDB6-4D64-A7CE-C46DF9A839D7

Q28301805-3D12FD57-AD4E-4ACA-AE63-1E7CB91D0ED1

P2888

Q28301805-3C291C20-748A-45BE-9939-929F143FF4A6

P304

Q28301805-499570AB-1012-4484-ADEC-7264E169DB39

P31

Q28301805-6ACF4A46-0E3C-40AF-9728-66539AEF82BD

P3181

Q28301805-D3A193ED-CED2-4500-BB1E-FDC7CD42038D

P356

Q28301805-C316E1C5-58D9-4B1C-A631-F4E8F6265E63

P407

Q28301805-365700C8-74DB-4A70-9173-FCCD1017C3F9

P433

Q28301805-247840D0-2F7E-4B8A-A2F8-CC3B65E96DD3

P478

Q28301805-2CBAC746-1FF6-43D1-A2A1-51E7D2783E3E

P577

Q28301805-513C711D-375A-4EFB-859B-42CF579A9D8A

P5875

Q28301805-E99CFED3-2F33-4C74-ABB3-69B24BE4F408

P6179

Q28301805-41D1910E-7420-466D-99CE-5D38ADA919A0

P698

Q28301805-E21C5417-2588-4A59-9E4D-99851FF71A8A

P932

Q28301805-BA539BA2-BABF-4BB5-8BDE-6C7158015A4D

P3181

P356

S10549-010-1312-2

P1433

Breast Cancer Research and Treatment

P1476

Significance of ER-Src axis in hormonal therapy resistance

@en

P2093

Binoj C Nair

http://www.w3.org/2001/XMLSchema#string

Dimple Chakravarty

http://www.w3.org/2001/XMLSchema#string

Rajeshwar Rao Tekmal

http://www.w3.org/2001/XMLSchema#string

Rambabu Challa

http://www.w3.org/2001/XMLSchema#string

Ratna K Vadlamudi

http://www.w3.org/2001/XMLSchema#string

Sreeram Vallabhaneni

http://www.w3.org/2001/XMLSchema#string

Valerie Cortez

http://www.w3.org/2001/XMLSchema#string

P2860

Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein

Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR

Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription

Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha

Coregulator function: a key to understanding tissue specificity of selective receptor modulators

Extranuclear coactivator signaling confers insensitivity to tamoxifen

The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype

Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells

Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets

Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes

P2888

s10549-010-1312-2

P304

377-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

731196

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S10549-010-1312-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49707908

http://www.w3.org/2001/XMLSchema#string

P6179

1017321336

http://www.w3.org/2001/XMLSchema#string

P698

21184269

http://www.w3.org/2001/XMLSchema#string

P932

3243930

http://www.w3.org/2001/XMLSchema#string